Success Story: From Pharmaceutical Innovation to Extraordinary Ability Recognition: EB-1A Approval After RFE for a Pharmaceutical Science Researcher
Client’s Testimonial:
"Thank you very much for all your hard work and support throughout my EB-1A petition. I am thrilled to receive the approval, and I truly appreciate your professionalism and dedication during this process.”
On July 9th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for an ORISE Fellow in the Field of Pharmaceutical Science (Approval Notice).
General Field: Pharmaceutical Science
Position at the Time of Case Filing: ORISE Fellow
Country of Origin: China
Approval Notice Date: July 9th, 2026
Processing Time: 15 months, 22 days (Premium Processing Upgrade Requested)
Case Summary:
The EB-1A (Alien of Extraordinary Ability) category requires petitioners to demonstrate sustained national or international acclaim and show that they have risen to the very top of their field. We are pleased to share the successful approval of an EB-1A petition after a Request for Evidence (RFE) for a client whose work has advanced pharmaceutical science through innovations in drug formulation, pharmaceutical 3D printing, and regulatory science.
With both a Ph.D. and an M.S. in pharmaceutics and drug delivery, the client has established expertise in pharmaceutical science, particularly in small molecule formulation, pharmaceutical 3D printing, and pharmaceutical regulations. The client's research is especially recognized for developing new approaches to fabricating bilayer tablets using hot melt extrusion-based dual-nozzle fused deposition modeling (FDM) 3D printing. At the time of filing, the client was continuing research in pharmaceutical science with the goal of developing safer, more effective, and more personalized drug delivery technologies while also contributing to regulatory science and pharmaceutical manufacturing.
Rather than relying on a single achievement, we demonstrated extraordinary ability by presenting a comprehensive record of sustained accomplishments that reflected the client's influence across multiple areas of pharmaceutical research.
The client's credentials included:
- 11 peer-reviewed journal articles, including 5 first-authored publications.
- 180 citations to published research.
- At least 17 completed peer reviews for scholarly journals.
- Research funding from the National Institute of General Medical Sciences (NIGMS).
Throughout the petition, we explained why these accomplishments carried significance under the EB-1A framework. The client's publication record showed consistent productivity in competitive scientific journals, while the citation history demonstrated that researchers around the world had independently relied upon the client's findings to advance their own investigations in pharmaceutical formulation, personalized drug delivery, and gene therapy manufacturing. We also emphasized that invitations to review manuscripts for respected journals reflected recognition of the client's expertise by journal editors responsible for maintaining scientific quality. In addition, research funding from the National Institute of General Medical Sciences provided independent evidence that the client's work addressed important scientific challenges with meaningful potential for public benefit.
To further establish sustained acclaim, we submitted seven recommendation letters from experts familiar with the client's scientific contributions. These letters explained how the client's innovations had influenced ongoing pharmaceutical research, highlighted the originality of the research program, and described why the client had become a recognized authority in several specialized areas of pharmaceutical science. One expert stated that:
“His results have proven essential to the continued development of effective drugs, and it is my belief that his work in the United States must remain unimpeded.”
After receiving the RFE, we prepared a detailed response that placed the client's achievements into the broader context of the EB-1A final merits determination. By demonstrating not only that the regulatory criteria were satisfied but also that the totality of the evidence reflected sustained recognition and influence within pharmaceutical science, we established that the client had reached the level of expertise required for classification as an individual of extraordinary ability. We are delighted that USCIS approved the EB-1A petition and congratulate the client on this outstanding achievement.
We look forward to the client's continued contributions to pharmaceutical innovation and drug delivery research in the United States.